B cell lymphoma 2 (Bcl-2) homology domain 3 (BH3)–only proteins of the Bcl-2 family are important functional adaptors that link cell death signals to the activation of Bax and/or Bak. The BH3-only protein Nbk/Bik induces cell death via an entirely Bax-dependent/Bak-independent mechanism. In contrast, cell death induced by the short splice variant of Bcl-x depends on Bak but not Bax. This indicates that Bak is functional but fails to become activated by Nbk. Here, we show that binding of myeloid cell leukemia 1 (Mcl-1) to Bak persists after Nbk expression and inhibits Nbk-induced apoptosis in Bax-deficient cells. In contrast, the BH3-only protein Puma disrupts Mcl-1–Bak interaction and triggers cell death via both Bax and Bak. Targeted knockdown of Mcl-1 overcomes inhibition of Bak and allows for Bak activation by Nbk. Thus, Nbk is held in check by Mcl-1 that interferes with activation of Bak. The finding that different BH3-only proteins rely specifically on Bax, Bak, or both has important implications for the design of anticancer drugs targeting Bcl-2.
Skip Nav Destination
Article navigation
19 November 2007
Article|
November 19 2007
Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis
Bernhard Gillissen,
Bernhard Gillissen
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Search for other works by this author on:
Frank Essmann,
Frank Essmann
3Institute of Molecular Medicine, Heinrich Heine University, 40225 Düsseldorf, Germany
Search for other works by this author on:
Philipp G. Hemmati,
Philipp G. Hemmati
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Search for other works by this author on:
Antje Richter,
Antje Richter
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Search for other works by this author on:
Anja Richter,
Anja Richter
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Search for other works by this author on:
Ilker Öztop,
Ilker Öztop
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Search for other works by this author on:
Govindaswamy Chinnadurai,
Govindaswamy Chinnadurai
4Institute for Molecular Virology, Saint Louis University School of Medicine, St. Louis, MO 63110
Search for other works by this author on:
Bernd Dörken,
Bernd Dörken
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
2Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
Search for other works by this author on:
Peter T. Daniel
Peter T. Daniel
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
2Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
Search for other works by this author on:
Bernhard Gillissen
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Frank Essmann
3Institute of Molecular Medicine, Heinrich Heine University, 40225 Düsseldorf, Germany
Philipp G. Hemmati
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Antje Richter
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Anja Richter
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Ilker Öztop
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
Govindaswamy Chinnadurai
4Institute for Molecular Virology, Saint Louis University School of Medicine, St. Louis, MO 63110
Bernd Dörken
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
2Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
Peter T. Daniel
1Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité, 13125 Berlin, Germany
2Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
Correspondence to Peter Daniel: [email protected]
Abbreviations used in this paper: Bcl, B cell lymphoma; BH, Bcl-2 homology; CMV, cytomegalovirus; Mcl, myeloid cell leukemia; PI, propidium iodide; wt, wild type.
Received:
March 07 2007
Accepted:
October 23 2007
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2007
J Cell Biol (2007) 179 (4): 701–715.
Article history
Received:
March 07 2007
Accepted:
October 23 2007
Citation
Bernhard Gillissen, Frank Essmann, Philipp G. Hemmati, Antje Richter, Anja Richter, Ilker Öztop, Govindaswamy Chinnadurai, Bernd Dörken, Peter T. Daniel; Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis . J Cell Biol 19 November 2007; 179 (4): 701–715. doi: https://doi.org/10.1083/jcb.200703040
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement